Výsledky vyhledávání - "Bernard R, Rubin"

Comparison of nonrandomized trials with slow-release sodium fluoride with a randomized placebo-controlled trial in postmenopausal osteoporosis

Autor: Helen Graham, Neil A. Breslau, Charles Y.C. Pak, C. Conrad Johnston, Norman H. Bell, Craig D. Rubin, Richard Berger, Bernard R. Rubin, Beverley Adams-Huet, Angelo A. Licata, Sydney Lou Bonnick, William Fears, Khashayar Sakhaee, Joyce E. Ballard, Veronica K. Piziak

Publikováno v: Journal of Bone and Mineral Research. 11:160-168

The results of slow-release sodium fluoride (SR-NaF) treatment in two nonrandomized trials involving 65 patients with postmenopausal osteoporosis from the primary site and 121 patients from collaborative sites were compared with those obtained from 5

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba6f415b521f43e4e896290adb75289f
https://doi.org/10.1002/jbmr.5650110204

Zobrazit plný text záznamu

Association of baseline disease and patient characteristics with response to etoricoxib and indomethacin for acute gout

Autor: Qinfen Yu, Bernard R. Rubin, Sandra V. Navarra, Steven S. Smugar, Andrew M. Tershakovec

Publikováno v: Current Medical Research and Opinion. 23:1685-1691

Disease history and clinical features can influence treatment response in patients with acute gout. The purpose of this pooled subgroup analysis was to assess the association of baseline disease and patient characteristics with response to treatment

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8a6a83e98772fdb40777d3a117cf60a
https://doi.org/10.1185/030079907x210750

Zobrazit plný text záznamu

Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies

Autor: Brian Fitzgerald, Bernard R. Rubin, Joel M. Kremer, Steven S. Smugar, A. I. Sebba, Steven R. Bird, Clifton O. Bingham, K. O'Brien, Andrew M. Tershakovec, Gary E. Ruoff

Publikováno v: Rheumatology. 46:496-507

OBJECTIVE To compare the efficacy of etoricoxib 30 mg with the generally maximum recommended dose of celecoxib, 200 mg, in the treatment of osteoarthritis (OA) in two identically designed studies. METHODS Two multi-centre, 26-week, double-blind, plac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70cfcb318add4be2f6a9b6085edb16dd
https://doi.org/10.1093/rheumatology/kel296

Zobrazit plný text záznamu

Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: A randomized controlled trial

Autor: Daryl K. Najarian, Gregory P. Geba, John Londoño, Bernard R. Rubin, Zafer E. Ozturk, Sandra V. Navarra, Richard A. Petruschke, Keith G. Pryhuber, Robert Burton, Joseph Antigua, Erluo Chen, Margaret Lund

Publikováno v: Arthritis & Rheumatism. 50:598-606

Objective To evaluate the efficacy and safety of etoricoxib and indomethacin in the treatment of patients with acute gout. Methods A randomized, double-blind, active-comparator study was conducted at 42 sites. A total of 189 men and women (≥18 year

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::914306365752745fe0f71564a738788f
https://doi.org/10.1002/art.20007

Zobrazit plný text záznamu

The efficacy, tolerability, and safety of 1200 mg/d of oxaprozin and 1500 mg/d of nabumetone in the treatment of patients with osteoarthritis of the knee

Autor: Jacques Caldwell, F. Gilbert McMahon, Michael E. Kuss, Marshall Sack, Jitendra Ganju, Robert Trapp, William Makarowski, Howard Offenberg, Tomas S. Bocanegra, David Lee, Robert J. Noveck, Bernard R. Rubin, Susan R.N. Rush, David Sikes, James M. Ratliff, Arthur L. Weaver

Publikováno v: Clinical Therapeutics. 18:114-124

This 6-week, multicenter, double-masked, placebo-controlled study compared the efficacy, tolerability, and safety of the recommended starting dose of oxaprozin (1200 mg/d) and a 1500-mg/d dose of nabumetone in the treatment of patients with moderate-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f45180532c75f45ae857f0ddd9a6e190
https://doi.org/10.1016/s0149-2918(96)80184-6

Zobrazit plný text záznamu

Comparison of the efficacy and safety of oxaprozin and nabumetone in the treatment of patients with osteoarthritis of the knee

Autor: David Sikes, David Lee, Howard Offenberg, Tomas S. Bocanegra, Marshall Sack, William Makarowski, Susan R.N. Rush, Arthur L. Weaver, Robert Trapp, Bernard R. Rubin, F.Gilbert McMahon, Michael E. Kuss, Jitendra Ganju, Jacques Caldwell

Publikováno v: Clinical Therapeutics. 17:735-745

This multicenter, 6-week, double-blind, placebo-controlled, parallel-group study compared the efficacy and safety of oxaprozin 1200 mg once daily with that of nabumetone 1000 mg once daily in patients with moderate-to-severe osteoarthritis (OA) of th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2750217585198352a717d5aa7238a841
https://doi.org/10.1016/0149-2918(95)80050-6

Zobrazit plný text záznamu

Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis

Publikováno v: Arthritis & Rheumatism. 35:849-856

Objective. To assess the relative efficacy of methotrexate (MTX), azathioprine (AZA), and their combination in the treatment of rheumatoid arthritis (RA) in a double-blind, prospective, multicenter, controlled trial. Methods. Two hundred nine patient

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::49ce6626cb4c394d6cb3af62711cd527
https://doi.org/10.1002/art.1780350802

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání